Investor Relations

Explore information about IDEAYA's business, strategy, pipeline, and financial performance, as well as the latest updates for the investment community.

Download IDEAYA Highlights

Financial Information

Snapshot

This section of the IDEAYA Biosciences InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  IDEAYA Biosciences assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQIDYA
Beta(0.05)
Shares Outstanding87.9M
Average Volume (10 days)758.8K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.57)
Sales (TTM)$2.49
Book Value (MRQ)$10.67
Cash Flow (TTM)($0.98)
Cash (MRQ)$7.57

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy15
 
Buy1
 
Hold3
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Jeffrey Stein
Director
50,000
Buy
Mar 2, 2026
Briseno Andres Ruiz
Executive Officer
80,000
Acquire
Jan 30, 2026
Dorman Stuart
Chief Commercial Officer
155,000
Acquire
Jan 30, 2026
Bleharski Joshua
Chief Financial Officer
170,000
Acquire
Jan 30, 2026
Yujiro Hata
President and CEO
600,000
Acquire
Jan 30, 2026

Recent SEC Filings

3
New Insider
Jun 5, 2026
8-K
Company Events
Jun 3, 2026
8-K
Company Events
Jun 1, 2026
SCHEDULE 13G/A
SCHEDULE 13G/A
May 15, 2026
424B5
Prospectus
May 5, 2026
Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings and Analyst data provided by Zacks.
Insiders data provided by Morningstar.